lenalidomide has been researched along with edoxaban in 2 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (edoxaban) | Trials (edoxaban) | Recent Studies (post-2010) (edoxaban) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 910 | 178 | 873 |
| Protein | Taxonomy | lenalidomide (IC50) | edoxaban (IC50) |
|---|---|---|---|
| Coagulation factor X | Homo sapiens (human) | 0.0034 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawaguchi, M; Konuma, S; Nehashi, Y; Okuda, Y; Uchimura, N | 1 |
| Asada, H; Miyagawa, F; Miyao, M; Nishikawa, M; Ogawa, K; Yamamoto, S | 1 |
2 other study(ies) available for lenalidomide and edoxaban
| Article | Year |
|---|---|
[Successful treatment of venous thromboembolism with a Factor Xa inhibitor, edoxaban, in patients with lenalidomide-treated multiple myeloma].
Topics: Aged; Factor Xa Inhibitors; Female; Humans; Lenalidomide; Multiple Myeloma; Pyridines; Thalidomide; Thiazoles; Tomography, X-Ray Computed; Venous Thromboembolism | 2015 |
Predisposition to multi-drug hypersensitivity after administration of mogamulizumab.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Diuretics; Drug Eruptions; Esomeprazole; Factor Xa Inhibitors; Fatal Outcome; Female; Furosemide; Humans; Immunologic Factors; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Middle Aged; Proton Pump Inhibitors; Pyridines; Thiazoles; Trimethoprim, Sulfamethoxazole Drug Combination | 2018 |